Filing Overview
IN8bio, Inc. filed a Form 8-K dated June 3, 2024 under Item 8.01 (Other Events). The company is a Delaware corporation headquartered in New York and trades on Nasdaq under the symbol INAB. The filing relates to the company’s announcement of preliminary clinical data from its Phase 1 study of INB-200, presented in a poster at the 2024 American Society of Clinical Oncology Annual Meeting.
Financial and Operating Information
The filing does not provide revenue, profit or loss, cash flow, cash balance, margins, debt, liquidity, or other financial metrics.
Material Changes Versus Prior Period
The filing text does not provide a comparison with a prior period. It reports the release of preliminary clinical data from the Phase 1 INB-200 study but does not include the underlying clinical results.
Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, an outlook, risk-factor updates, contingencies, or unusual financial items. The referenced clinical data are preliminary, and the filing incorporates Exhibit 99.1, a June 3, 2024 press release containing the announcement; the press release text is not included in the provided filing content.
Key Facts to Verify
- Review Exhibit 99.1 for the specific preliminary Phase 1 INB-200 clinical results, patient population, endpoints, safety findings, and efficacy data.
- Verify any limitations, disclaimers, or subsequent-development statements in the associated poster and press release.
- Consult the company’s latest periodic filing for current cash, operating expenses, liquidity, financing requirements, and going-concern considerations.
- Confirm that the filing was signed by Patrick McCall, Chief Financial Officer and Secretary, on June 3, 2024.